Tuberculosis Diagnostic
Tuberculosis
Research/ExploratoryActive
Key Facts
About GenEndeavor
GenEndeavor is a private, pre-revenue diagnostics company developing a proprietary Non-Enzymatic Amplification Technologies (NEAT) platform aimed at revolutionizing molecular diagnostics. The company's initial focus is on creating an accessible diagnostic tool for the early detection of ovarian cancer, with a broader vision to impact genetic diseases, infectious diseases like tuberculosis, and agricultural trait screening. Led by founder and CEO Ricardo Mancebo, the company is actively engaging with investors and global partners to advance its technology and pipeline.
View full company profileTherapeutic Areas
Other Tuberculosis Drugs
| Drug | Company | Phase |
|---|---|---|
| Vaxine TB Vaccine | Vaxine | Preclinical |
| Isoniazid Oral Solution, USP | CMP Pharma | Approved |
| Tuberculosis Program | Fimbrion Therapeutics | Preclinical |
| Undisclosed Program | Crestone | Preclinical |
| TB Screening LFA | DiagMetrics | Development |
| RGFields for Tuberculosis | Anapole Technologies | Pre-clinical |
| Tuberculosis Nanobody | VicuTec Biologicals | Pre-clinical |
| Not specified on provided pages | Cadila Pharmaceuticals | Commercial (World's First Claim) |
| TB Diagnostic & Drug Discovery | Avesthagen | Research/Discovery |
| ALF Platform | Senzo | Pre-clinical |
| Satiro Tablets | KYORIN Pharmaceutical | Registration |